Answers are grounded in this paper and cite their sources.
Analysis reveals potential FDA-approved drugs for CTNNB1 syndrome treatment, suggesting new therapeutic strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Vergis et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: